Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.1 USD | +2.57% | +0.19% | +2.35% |
Feb. 27 | Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance | MT |
Feb. 27 | Transcript : Ligand Pharmaceuticals Incorporated, Q4 2023 Earnings Call, Feb 27, 2024 |
Evolution of the average Target Price on Ligand Pharmaceuticals Incorporated
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Ligand Pharmaceuticals Incorporated
Barclays | |
Roth Capital Partners | |
HC Wainwright | |
CJS Securities | |
Stephens Inc. | |
Benchmark Capital | |
Craig-Hallum |
EPS Revisions
- Stock
- Equities
- Stock Ligand Pharmaceuticals Incorporated - Nasdaq
- Consensus Ligand Pharmaceuticals Incorporated